Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
turoctocog alfa (NovoEight®)
Reference No. 1634
Publication date:
08/05/2014
Appraisal information
turoctocog alfa (NovoEight®) 250 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 500 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 1000 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 1500 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 2000 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 3000 units powder and solvent for solution for injection
Company:
Novo Nordisk Ltd
BNF category:
Cardiovascular system
NMG meeting date:
Not scheduled
AWMSG meeting date:
Not scheduled
Submission Type:
Nonsubmission
Status:
Not endorsed
Advice No:
Not available
Ratification by Welsh Government:
07/05/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
In the absence of a submission from the holder of the marketing authorisation, turoctocog alfa (NovoEight®) cannot be endorsed for use within NHS Wales for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Statement of Advice (SOA)
Download
turoctocog alfa (NovoEight) 1634 SOA
